# United Therapeutics (UTHR) — News

UTHR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/uthr/news

## Recent headlines

- [Liquidia shares jump 42% after settlement with United Therapeutics](https://www.ainvest.com/news/liquidia-shares-jump-42-settlement-united-therapeutics-2610) — AInvest Wire, Oct 14, 2026
  Liquidia Corporation (NASDAQ: LQDA) shares surged 42% on October 14, 2026, following a reported settlement with United Therapeutics, resolving a long-standing patent dispute over Liquidia’s Yutrepia inhalation powder. The settlement comes after a U.S. District Court in Delaware ruled earlier in the…
- [United Therapeutics Corp - Liquidia to terminate ascent trial cohorts studying PH-ILD and cease data publication - SEC filing](https://www.ainvest.com/news/united-therapeutics-corp-liquidia-terminate-ascent-trial-cohorts-studying-ph-ild-cease-data-publication-sec-filing-2610) — AInvest Wire, Oct 14, 2026
- [United Therapeutics Corp - Liquidia to cease sales of Yutrepia with PH-ILD indication upon FDA approval - SEC filing](https://www.ainvest.com/news/united-therapeutics-corp-liquidia-cease-sales-yutrepia-ph-ild-indication-fda-approval-sec-filing-2610) — AInvest Wire, Oct 14, 2026
  Liquidia Corporation (NASDAQ: LQDA) announced on June 2, 2025, that it had scheduled the first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, following its FDA approval on May 23 , 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension…
- [United Therapeutics Corp - Enters settlement agreement with Liquidia to resolve litigation - SEC filing](https://www.ainvest.com/news/united-therapeutics-corp-enters-settlement-agreement-liquidia-resolve-litigation-sec-filing-2610) — AInvest Wire, Oct 14, 2026
  United Therapeutics Corporation (Nasdaq: UTHR) has reached a settlement agreement with Liquidia Technologies, Inc. to resolve ongoing litigation related to patent infringement. The resolution follows a court ruling that found Liquidia infringing on two claims of United Therapeutics’ U.S. Patent No.…
- [Liquidia Corporation: BTIG raises to buy from neutral](https://www.ainvest.com/news/liquidia-corporation-btig-raises-buy-neutral-2610) — AInvest Wire, Oct 14, 2026
  BTIG has raised its price target for Liquidia Corporation (NASDAQ: LQDA) and maintained a "Buy" rating, reflecting stronger-than-expected adoption of the company’s drug candidate, YUTREPIA. The firm increased its 2025 revenue forecast for YUTREPIA from $26.5 million to $76.4 million and projected…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).